NextCure launches up to $14.5M at-the-market offering; shares sold at prevailing prices

Filed December 19, 2025 · ~1 min read

Key Changes

• high

  NextCure may sell up to $14.5 million of common stock through an at-the-market facility with H.C. Wainwright as agent; no minimum amount is guaranteed.

  The Offering verify on EDGAR →
• medium

  Proceeds are earmarked for general corporate purposes and working capital, including preclinical studies and clinical trials; management has broad discretion.

  Use of Proceeds verify on EDGAR →
• medium

  The company recently completed a private placement raising $21.5 million gross and effected a 1-for-12 reverse stock split in July 2025.

  Prospectus Summary verify on EDGAR →